Holen Sie sich die Stockscreener-App
6.805
0.81%
0.055
Schlusskurs vom Vortag:
$6.75
Offen:
$6.85
24-Stunden-Volumen:
13,826
Relative Volume:
0.19
Marktkapitalisierung:
$141.76M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-24.87M
KGV:
-5.1557
EPS:
-1.3199
Netto-Cashflow:
$-23.65M
1W Leistung:
-2.65%
1M Leistung:
-2.51%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$6.67
$7.0012
1-Wochen-Bereich:
$6.67
$7.46
52-Wochen-Spanne:
$5.50
$13.39
Satellos Bioscience Inc Stock (MSLE) Company Profile
Firmenname
Satellos Bioscience Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare MSLE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
6.805 | 140.61M | 0 | -24.87M | -23.65M | -1.3199 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Satellos Bioscience Inc Stock (MSLE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-06 | Eingeleitet | Leerink Partners | Outperform |
| 2026-03-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
Satellos Bioscience Inc Aktie (MSLE) Neueste Nachrichten
Satellos Bioscience (MSLE) Slides 5.5% as Biotech Sector Headwinds Weigh on SentimentHidden Order - Newser
Satellos Bioscience Q1 2026 Earnings: Narrower Loss Reported, Stock Slips on Lack of Revenue Progress - Newser
Satellos Bioscience Inc. (MSLE) Q1 2026 Earnings: Narrower-Than-Expected Loss Marks Progress Amid Pre-Revenue StageCEO Earnings Statement - Newser
MSLE Stock Price, Quote & Chart | SATELLOS BIOSCIENCE INC (NASDAQ:MSLE) - ChartMill
CCORF Initiates Satellos Bioscience(MSLE.US) With Buy Rating, Announces Target Price $13.81 - Moomoo
Satellos Bioscience Sets June 17, 2026 Virtual Annual Shareholder Meeting - TipRanks
Virtual AGM, board elections and pay disclosure at Satellos Bioscience (NASDAQ: MSLE) - Stock Titan
MSLE Reiterated by HC Wainwright & Co. -- Price Target Maintained at $11 - GuruFocus
Satellos Bioscience Price Target Maintained With a $11.00/Share by HC Wainwright & Co. - Moomoo
Satellos Bioscience (MSLE) Q1 2026 Earnings: EPS $-0.53 Beats EstimatesHigh Attention Stocks - newser.com
Satellos Bioscience (TSX:MSCL) Extends Cash Runway Confidence - Kalkine Media
H.C. Wainwright Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $11 - Moomoo
We're Not Very Worried About Satellos Bioscience's (TSE:MSCL) Cash Burn Rate - Yahoo Finance
Stocks In Play - Baystreet.ca
Satellos Bioscience (MSLE) insiders report 1.14M shares, 7.35% stake - Stock Titan
Positive Developments for Satellos (MSLE) in Q1 2026 - GuruFocus
Satellos Bioscience Inc. - Baystreet.ca
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress - Investing News Network
Satellos Bioscience : First Quarter 2026 Management’s Discussion Analysis - marketscreener.com
Satellos Bioscience Posts Wider Q1 2026 Loss but Strengthens Balance Sheet - TipRanks
Satellos Bioscience: Q1 Earnings Snapshot - marketscreener.com
Satellos Bioscience (NASDAQ: MSLE) raises $57M and advances Duchenne trials - Stock Titan
MSLE Price Today: Satellos Bioscience Inc. Stock Price, Quote & Chart | MEXC - MEXC
Qiming reports 1.725M Satellos shares; MSLE ownership disclosure - Stock Titan
Number of shareholders of Satellos Bioscience Inc. – BOATS:MSLE - TradingView
What Satellos Bioscience (MSLE) is doing that separates it from the herd (+0.13%) 2026-05-11Alpha Picks - newser.com
Why Satellos Bioscience (MSLE) could be the anchor your portfolio needs (Smart Money Flows) 2026-05-08Real-time Trade Ideas - Newser
MSLE Satellos Bioscience stock rallies 7.7% despite 941% earnings miss, zero revenue as investors eye biotech potential.Social Flow Trades - Newser
Certain Stock Options of Satellos Bioscience Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2026. - marketscreener.com
Certain Pre-Funded Warrants of Satellos Bioscience Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2026. - marketscreener.com
Satellos Bioscience Inc expected to post a loss of 69 cents a shareEarnings Preview - TradingView
Guggenheim Initiates Satellos Bioscience(MSLE.US) With Buy Rating, Announces Target Price $23 - Moomoo
Guggenheim Initiates Satellos Bioscience at Buy With CA$31.43 Price Target - Moomoo
Satellos launches public offering, applies for Nasdaq listing - MSN
Satellos Bioscience to Present at Annual MDA Clinical and Scientific Conference and Insights in Research Investor Summit - TMX Newsfile
Satellos Bioscience (NASDAQ:MSLE) Downgraded by Wall Street Zen to "Strong Sell" - MarketBeat
Satellos prices $50M public offering - MSN
MSLE Satellos Bioscience Inc. reports far wider than expected Q4 2025 loss while its shares post modest gains amid positive investor sentiment.Viral Momentum Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Satellos Bioscience (MSLE) Stock: Portfolio Allocation (Bearish Sentiment) 2026-04-20Community Chart Signals - Xã Châu Thành
MSLE : Satellos Bioscience Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
MSLE: Satellos Bioscience Inc.Insider Transations - Zacks Investment Research
Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference - Investing News Network
Satellos Bioscience to Showcase DMD Program at April Bloom Burton Healthcare Investor Conference - TipRanks
Satellos Bioscience (NASDAQ: MSLE) plans Bloom Burton investor conference presentation - Stock Titan
Satellos Bioscience (NASDAQ:MSLE) Coverage Initiated by Analysts at Leerink Partners - Defense World
Satellos Bioscience Inc. (NASDAQ:MSLE) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Satellos Bioscience (NASDAQ:MSLE) Now Covered by Analysts at Leerink Partners - MarketBeat
Finanzdaten der Satellos Bioscience Inc-Aktie (MSLE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):